Evidence map›Paper›PMID 26423520›Full record

ArticleJournal of lipid research2016

Simplified assays of lipolysis enzymes for drug discovery and specificity assessment of known inhibitors.

Jose Iglesias, Julien Lamontagne, Heidi Erb, Sari Gezzar, Shangang Zhao, Erik Joly, Vouy Linh Truong, Kathryn Skorey, Sheldon Crane, S R Murthy Madiraju and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. PPARα regulates ER-lipid droplet protein Calsyntenin-3β to promote ketogenesis in hepatocytes.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Anti-Inflammatory Effect of Ethanolic Extract fromMolecules (Basel, Switzerland) · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jose IglesiasMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9.
Julien LamontagneMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9.
Heidi ErbMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9.
Sari GezzarMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9.
Shangang ZhaoMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9.
Erik JolyMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9.
Vouy Linh TruongNuChem Therapeutics, Montréal, Québec, Canada, H4P 2R2.
Kathryn SkoreyNuChem Therapeutics, Montréal, Québec, Canada, H4P 2R2.
Sheldon CraneNuChem Therapeutics, Montréal, Québec, Canada, H4P 2R2.
S R Murthy MadirajuMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9 marc.prentki@umontreal.ca murthy.madiraju@crchum.qc.ca.
Marc PrentkiMolecular Nutrition Unit and Montreal Diabetes Research Center, CRCHUM, Montréal, Québec, Canada H2X 0A9 Departments of Nutrition, Biochemistry, and Molecular Medicine, Université de Montréal, Montréal, Québec, Canada H2X 0A9 marc.prentki@umontreal.ca murthy.madiraju@crchum.qc.ca.
Université de Montréal · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Lipids are used as cellular building blocks and condensed energy stores and also act as signaling molecules. The glycerolipid/ fatty acid cycle, encompassing lipolysis and lipogenesis, generates many lipid signals. Reliable procedures are not available for measuring activities of several lipolytic enzymes for the purposes of drug screening, and this resulted in questionable selectivity of various known lipase inhibitors. We now describe simple assays for lipolytic enzymes, including adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), sn-1-diacylglycerol lipase (DAGL), monoacylglycerol lipase, α/β-hydrolase domain 6, and carboxylesterase 1 (CES1) using recombinant human and mouse enzymes either in cell extracts or using purified enzymes. We observed that many of the reported inhibitors lack specificity. Thus, Cay10499 (HSL inhibitor) and RHC20867 (DAGL inhibitor) also inhibit other lipases. Marked differences in the inhibitor sensitivities of human ATGL and HSL compared with the corresponding mouse enzymes was noticed. Thus, ATGListatin inhibited mouse ATGL but not human ATGL, and the HSL inhibitors WWL11 and Compound 13f were effective against mouse enzyme but much less potent against human enzyme. Many of these lipase inhibitors also inhibited human CES1. Results describe reliable assays for measuring lipase activities that are amenable for drug screening and also caution about the specificity of the many earlier described lipase inhibitors.

Indexed as

AcyltransferasesAdipose TissueAnimalsCarboxylic Ester HydrolasesDrug DiscoveryEnzyme InhibitorsFatty AcidsHumansLipaseLipogenesisLipolysisLipoprotein LipaseMiceMonoacylglycerol LipasesSterol EsteraseTriglyceridesAcyltransferasesCarboxylic Ester HydrolasesCES1 protein, humanEnzyme InhibitorsFatty AcidsLipaseLipoprotein LipaseMonoacylglycerol LipasesPNPLA2 protein, humanPNPLA2 protein, mouseSterol EsteraseTriglyceridesadipose triglyceride lipasealpha/beta hydrolase domain 6diacylglycerol lipasefatty acid amide hydrolasehormone sensitive lipasemonoacylglycerol lipase

Identifiers

PMID26423520
PMCPMC4689331
OpenAlexW2319953058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.